Scientific American

Anthropic warns AI could soon start improving itself. Critics aren’t convinced

The maker of Claude wants AI labs, including itself, to prepare for a coordinated slowdown if models begin building their own ...

Anthropic calls for global pause in AI development before humans lose control

Anthropic PBC has sounded the alarm on the rapid pace of artificial intelligence development and is calling on the world’s ...
The Hacker News

ThreatsDay Bulletin: Claude Security Plugin, Azure Priv-Esc, Kali365 MFA Bypass, FIFA Scams +15 More

Massive regional C2 footprint More than 1.3K C2 Servers Discovered in the Middle East Hunt.io said it identified more than ...
IEEE

Recursive Learning Framework for Structured Data Agglomeration

Abstract: In the current era, vast amounts of data are readily available, particularly in the form of multi-structured data such as sequences, trees, and graphs. Analyzing these diverse data types ...
Nasdaq

MIT and Recursion Unveil Boltz-2: A Revolutionary Open-Source Biomolecular Co-Folding Model with Advanced Structure and Binding Affinity Prediction

Boltz-2 is an open-source biomolecular model achieving near-FEP accuracy with 1000x faster predictions for structure and binding affinity. MIT and Recursion have released Boltz-2, the first ...
Yahoo Finance

Artificial Intelligence in Drug Discovery Market Outlook Report 2025-2030: Accelerating Drug Discovery as Pharma Embraces Machine Learning and Data-Driven Innovations

Artificial Intelligence (AI) in Drug Discovery Market · GlobeNewswire Inc. Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The "Artificial Intelligence (AI) in Drug Discovery Market - Global Outlook & ...
BioSpace

Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference

Met primary endpoint of safety and tolerability in CCM patients with no treatment-related discontinuations or Grade 3 adverse events In comparison to placebo, treatment with REC-994 400 mg showed ...
TMCnet

Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of ...

SALT LAKE CITY, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced top-line results of ...
The Motley Fool

Is Recursion Pharmaceuticals Stock a Buy?

The process of developing novel medicines is notoriously complicated, expensive, and long. Though you might think it's getting faster and cheaper thanks to technological breakthroughs, the opposite is ...